Symptoms & Symptom Management
Management of Advanced Pleural Mesothelioma-At the Crossroads
JCO Oncology Practice 2021 September 7 [Link] Anna K Nowak, Alannah Jackson, Calvin Sidhu Abstract The management of pleural mesothelioma has changed with the demonstration that first-line checkpoint blockade therapy improves survival. This review covers issues of relevance to the practicing medical oncologist, with an emphasis on the palliative setting and on new information. Until…
Read MoreProfile of soluble factors in pleural effusions predict prognosis in mesothelioma
Cancer Biomarkers 2021 August 24 [Link] I M Dick, Y C G Lee, H M Cheah, A Miranda, B W S Robinson, J Creaney Abstract Background: Pleural mesothelioma is a deadly asbestos induced cancer. Less than 10% of mesothelioma patients survive 5 years post diagnosis. However survival can range from a few months to a…
Read MoreEvidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology
Cancer Cytopathology 2021 September 3 [Link] Ilaria Girolami, Ersilia Lucenteforte, Albino Eccher, Stefano Marletta, Matteo Brunelli, Paolo Graziano, Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone, Aldo Scarpa, Tao Huang, Liron Pantanowitz Abstract Cytology effusions are often the only material available for diagnosing malignant pleural mesothelioma (MPM). However, the cytomorphological features alone are not always diagnostic, and…
Read MoreState of the art cytology of pleural fluid, focusing on the diagnosis of mesothelioma
Cytopathology 2021 September 1 [Link] Sara E Monaco, Luka Brcic, Sanja Dacic Abstract Objective: Mesothelioma has always been a challenging diagnosis to render in body cavity cytology samples. This review is a timely update on pleural fluid cytology and ancillary studies that should be considered in the diagnosis of mesothelial proliferations, specifically mesotheliomas. Methods: Information…
Read MoreCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up
International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…
Read MoreThe association between pleural fluid exposure and survival in pleural mesothelioma
Chest 2021 June 10 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M Rahman Abstract Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may…
Read MoreThe value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)
Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue samples; however, effusion cytology offers an opportunity to identify a strong possibility for mesothelioma diagnosis at an early stage. We conducted a retrospective analysis of…
Read MoreDiagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…
Read MoreThe association between pleural fluid exposure and survival in pleural mesothelioma
Chest 2021 June 10 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M Rahman Abstract Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may…
Read MorePleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation
Frontiers in Oncology 2021 April 28 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Xuan Yao, Megat Abd Hamid, Rachel M Mercer, Maged Hassan, Eihab O Bedawi, Melissa Dobson, Peter Fsadni, Stephen Montefort, Tao Dong, Najib M Rahman, Ioannis Psallidas Abstract Objectives: Patients with malignant pleural mesothelioma (MPM) or pleural metastases often present with malignant pleural effusion…
Read More